Who is sponsoring NCT03854357?

NCT03854357 is sponsored by Henry Ford Health System.

What drugs are being tested in NCT03854357?

Interventions in NCT03854357: Subscapularis Rehabilitation, Standard Rehabilitation.

What condition does NCT03854357 study?

NCT03854357 studies Shoulder Osteoarthritis.

Is NCT03854357 still recruiting?

NCT03854357 is currently completed. Last updated 4 November 2022.

Last reviewed 2022-11-04 · How we verify

NCT03854357

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Subscapularis Strength After Total Shoulder Arthroplasty

Completed NA Last updated 4 November 2022

What this trial tests

NA trial testing Subscapularis Rehabilitation in Shoulder Osteoarthritis in 66 participants. Completed in 31 March 2022.

Timeline

2 October 2018

Primary endpoint
31 March 2021

31 March 2022

Quick facts

Lead sponsor	Henry Ford Health System
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	quadruple
Primary purpose	treatment
Enrollment	66
Start date	2 October 2018
Primary completion	31 March 2021
Estimated completion	31 March 2022
Sites	1 location across United States

Drugs / interventions tested

Subscapularis Rehabilitation
Standard Rehabilitation

Conditions studied

Shoulder Osteoarthritis — all drugs for Shoulder Osteoarthritis →

Sponsor

Henry Ford Health System — full company profile →

Who can join

18 and older, any sex, with Shoulder Osteoarthritis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a randomized, double-blinded, standard of care-controlled clinical trial. The purpose of this study is to determine the difference in subscapularis strength and function after anatomic Total Shoulder Arthroplasty (aTSA) in patients who receive isolated subscapularis rehabilitation in addition to the standard rehabilitation after surgery at 12-month follow up. Specifically the investigators will measure subscapularis strength utilizing a dynamometer device and subscapularis function utilizing isolated subscapularis physical examination testing: belly-press, bear-hug, and lift-off tests. Additionally, investigators will document secondary outcome measures including shoulder range of motion and Patient Reported Outcome Measure Information System (PROMIS) questionnaire scores.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other recruiting trials for Shoulder Osteoarthritis

Currently open trials in the same condition.

NCT07347054 — Clinical Study of Myofascial Trigger Points(MTrPs) Injection in the Treatment of Shoulder Osteoarthritis(OA) · NA · recruiting
NCT06381791 — CBD for Pain Following Orthopedic Shoulder Surgery · Phase 1, PHASE2 · recruiting
NCT06319911 — AETOS Shoulder System · recruiting
NCT06025448 — Is MIO-RSA Noninferior to BIO-RSA When it Comes to Mechanical Implant Stability? · NA · recruiting
NCT06025331 — Does BIO-RSA Provides Superior Clinical Outcome Compared to Conventional RSA? · NA · recruiting

Other Henry Ford Health System trials

Trials by the same sponsor.

NCT07450183 — Perioperative Cemiplimab for Resectable Non-Small Cell Lung Cancer With High PD-L1 · Phase 2 · not yet recruiting
NCT07418853 — Comparison of Goniotomy Device Outcomes in Combined Phacoemulsification-goniotomy Surgeries · NA · not yet recruiting
NCT06670287 — The Use of Multiple Sensors to Track Sleep in Nightshift Workers · NA · recruiting
NCT07363525 — Michigan Initial Experience Using Tigertriever for Thrombectomy · not yet recruiting
NCT07530172 — Radioembolization Versus External Radiation Therapy · Phase 2 · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03854357 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Henry Ford Health System
Last refreshed: 4 November 2022

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03854357.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing